Core Insights - Centene reported revenue of 40.81billionforthequarterendedDecember2024,reflectingayear−over−yearincreaseof3.438.96 billion by 4.75% [1] - The company's EPS for the quarter was 0.80,significantlyhigherthanthe0.45 reported in the same quarter last year, resulting in an EPS surprise of 63.27% compared to the consensus estimate of 0.49[1]FinancialPerformanceMetrics−TotalMedicalHealthBenefitslossratiowasreportedat89.636.30 billion, surpassing the average estimate of 35.50billionandshowingayear−over−yearincreaseof2.735.52 billion, exceeding the estimate of 34.71billionandreflectinga3.8777 million, slightly below the average estimate of 782.17million,markingasignificantyear−over−yeardeclineof29.84.51 billion, well above the average estimate of 3.07billion,representingayear−over−yearincreaseof9.48.72 billion, exceeding the estimate of 8.47billionandshowingayear−over−yearincreaseof17.85.48 billion, slightly below the average estimate of 5.70billion,withayear−over−yearincreaseof3.520.83 billion, surpassing the average estimate of 20.16billion,butreflectingayear−over−yeardeclineof1.41.27 billion, exceeding the estimate of $1.19 billion, but showing a year-over-year decline of 16.8% [4] Stock Performance - Centene's shares have returned 3.4% over the past month, outperforming the Zacks S&P 500 composite, which saw a 1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]